DK0946199T3 - TGF betal 1-responsive celler fra knoglemarv - Google Patents

TGF betal 1-responsive celler fra knoglemarv

Info

Publication number
DK0946199T3
DK0946199T3 DK97947454T DK97947454T DK0946199T3 DK 0946199 T3 DK0946199 T3 DK 0946199T3 DK 97947454 T DK97947454 T DK 97947454T DK 97947454 T DK97947454 T DK 97947454T DK 0946199 T3 DK0946199 T3 DK 0946199T3
Authority
DK
Denmark
Prior art keywords
bone marrow
cells
tgf
pays
marrow cells
Prior art date
Application number
DK97947454T
Other languages
English (en)
Inventor
Erlinda Maria Gordon
Frederick L Hall
W French Anderson
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK0946199T3 publication Critical patent/DK0946199T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK97947454T 1996-11-12 1997-11-12 TGF betal 1-responsive celler fra knoglemarv DK0946199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/747,514 US6063593A (en) 1996-11-12 1996-11-12 TGFβ1 responsive bone marrow derived cells to express a recombinant protein
PCT/US1997/020558 WO1998020907A1 (en) 1996-11-12 1997-11-12 TGFβ1-RESPONSIVE CELLS FROM BONE MARROW

Publications (1)

Publication Number Publication Date
DK0946199T3 true DK0946199T3 (da) 2008-08-25

Family

ID=25005386

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97947454T DK0946199T3 (da) 1996-11-12 1997-11-12 TGF betal 1-responsive celler fra knoglemarv

Country Status (12)

Country Link
US (4) US6063593A (da)
EP (1) EP0946199B1 (da)
JP (2) JP2001503989A (da)
AT (1) ATE397461T1 (da)
AU (1) AU5253498A (da)
CA (1) CA2271734A1 (da)
DE (1) DE69738753D1 (da)
DK (1) DK0946199T3 (da)
ES (1) ES2308790T3 (da)
NZ (1) NZ335753A (da)
PT (1) PT946199E (da)
WO (1) WO1998020907A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
JP2003524407A (ja) 1999-07-20 2003-08-19 ユニバーシティ オブ サザン カリフォルニア 多能性前−間葉、前−造血先祖幹細胞の同定
JP2003018984A (ja) * 2001-07-06 2003-01-21 Mitsubishi Chemicals Corp 多分化能を有する細胞の製造法
WO2003051283A2 (en) * 2001-10-26 2003-06-26 The Children's Hospital Of Philadelphia Engineered bone marrow
WO2003073998A2 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
NZ535487A (en) * 2002-04-01 2008-12-24 Univ Texas Medical Branch Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
US20040052771A1 (en) * 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
EP1563058A4 (en) * 2002-07-12 2005-12-28 Univ Singapore Haemangioblasts-Progenitor Cells
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
EP1713513B1 (en) 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
JP2006249072A (ja) * 2005-02-09 2006-09-21 Osaka Univ タンパク質導入用担体、前記担体を用いたタンパク質導入剤、タンパク質導入方法、およびタンパク質導入細胞ならびにその製造方法
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
CA2649333C (en) 2006-04-14 2016-10-04 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
EP2170975B1 (en) 2007-07-10 2018-05-02 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
WO2009137624A2 (en) 2008-05-06 2009-11-12 Advanced Cell Technology, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
KR20190000928A (ko) 2008-05-06 2019-01-03 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US8583299B2 (en) * 2009-03-17 2013-11-12 General Electric Company System and method for communicating data in a train having one or more locomotive consists
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2016054107A1 (en) 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers
US11406721B2 (en) 2016-02-22 2022-08-09 The Regents Of The University Of California Compositions and methods for imaging cell populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein

Also Published As

Publication number Publication date
PT946199E (pt) 2008-09-01
JP2008206520A (ja) 2008-09-11
US20020141982A1 (en) 2002-10-03
NZ335753A (en) 2001-02-23
DE69738753D1 (de) 2008-07-17
CA2271734A1 (en) 1998-05-22
US6410015B1 (en) 2002-06-25
JP4767983B2 (ja) 2011-09-07
EP0946199B1 (en) 2008-06-04
US6844191B2 (en) 2005-01-18
EP0946199A1 (en) 1999-10-06
WO1998020907A1 (en) 1998-05-22
JP2001503989A (ja) 2001-03-27
ATE397461T1 (de) 2008-06-15
EP0946199A4 (en) 2002-11-27
AU5253498A (en) 1998-06-03
ES2308790T3 (es) 2008-12-01
US6063593A (en) 2000-05-16
US6277369B1 (en) 2001-08-21

Similar Documents

Publication Publication Date Title
DK0946199T3 (da) TGF betal 1-responsive celler fra knoglemarv
ATE358493T1 (de) Menschliche mesenchymale stammzellen aus peripherem blut
TW428026B (en) Bifunctional protein, preparation and use
HK1038307A1 (en) Thymosin beta 4 promotes wound repair.
NO20052949D0 (no) Implantat inneholdende dyrkede bruksceller og fremgangsmate for fremstilling
ATE313634T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
NZ331517A (en) A method for making and/or repairing cartilage in vivo by implanting a scaffold or framework in combination with periosteal/perichondrial tissue that holds the scaffold in place
DE69940507D1 (de) Biotechnisch erzeugte gefässprothese für die implantation
DE69527540T2 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
GR1002147B (en) Human tissue factor related dna segments poypeptides and antibodies
ES8800359A1 (es) Metodo de produccion de factor viii:c humano
WO1994010203A3 (en) Op-3-induced morphogenesis
DE69934694D1 (de) Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
EP1014880A4 (en) INCREASE OR REPAIR OF SKIN TISSUE, SUBCUTANEOUS OR VOICE ROPE ABNORMALITIES
DE68913991D1 (de) Implantat zur verwendung in der knochenchirurgie.
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
HU9802577D0 (en) In vivo dyeing material, process for producing thereof and use for identifying of living tissues
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
BR9708049A (pt) Processo para matar células alvo indesejadas em uma população de células imunotoxinas para matar células uso das mesmas e kit para realizar o processo
BR8202494A (pt) Processo para preparar tecido natural fixo bem como tecido natural fixo valvula cardiaca fixa de suino e tecido fixo de pericardio de bovino adequados para implante
WO2002050111A3 (en) Isolated laminin 10
DK0928294T3 (da) Fremgangsmåde og apparat til fremstilling af en acellulær rød blodlegeme-erstatning
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
EP2295578A3 (en) Cyp1b1 nucleic acids and methods of use
WO1994006447A3 (en) 60a protein-induced morphogenesis